Oncology中文 (CN version)

Benefiting Cancer Patients through an Innovative Oncology Platform

20150403-04

WuXi AppTec’s Oncology Business Unit is part of the solution and efficiently works with partners to advance cancer biology to cancer therapy by offering our oncology and immuno-oncology platforms. We have established comprehensive in vivo tumor model systems including human cancer cell line-derived xenograft models, murine syngeneic tumor models and patient-derived xenograft (PDX) models with in-depth genomic characterization. We offer leading CRISPR services and specialized tumor cell biology assays. The WuXi AppTec’s oncology team has significant experience in IND-enabling studies for successful FDA and CFDA filing either as stand alone in vivo study or as integrated drug discovery programs, and in translational oncology bridging clinical trials.

CRISPR
Precise targeted solution on CRISPR/Cas 9 gene editing platform.  (Learn More)

Tumor Models
Tumor model for small & large molecule drug discovery:
 Cell line-derived xenograft (CDX) tumor models. (Learn more)
 Patient-derived xenograft (PDX) tumor models. (Learn more)
➢ Syngeneic tumor models for Immuno-oncology. (Learn more)

Immuno-oncology
One stop service to enable cancer immunotherapy. (Learn More)

Translational Oncology
A bridge to connect preclinical research and clinical support. (Learn More)

2.1
The world 1st INTEGRATED tumor model online database. (Learn More)